Scientist in Blood Banking — BB(ASCP) Free Preparation Guide Study Guide

Apply it

A hematopoietic progenitor-cell transplant recipient requires red cells. The available unit is leukocyte reduced but lacks the required irradiation designation. Arrange the indicated irradiated component rather than assuming filtration has eliminated graft-versus-host disease risk.

Apply it

A patient has recurrent severe allergic reactions despite other preventive measures and still requires red-cell support. A washed component addresses residual plasma exposure; any separate requirements for antigen matching and irradiation must also be maintained.

Apply it

An infant needs rapid transfusion through central access. Two compatible irradiated units have different storage histories. Evaluate their extracellular-potassium risk and the prescribed preparation requirements before selecting the unit, rather than considering compatibility alone sufficient.

Apply it

A conventional platelet bag is found in a red-cell refrigerator after an undocumented interval. Quarantine it for assessment of the storage deviation. Do not return it to room-temperature inventory merely because its printed expiration has not passed.

Apply it

A rare compatible frozen unit is located for a multiply alloimmunized patient. Plan thawing and deglycerolization before issue, and confirm the resulting component's expiration. The frozen unit cannot be treated as ready for immediate infusion.

Apply it

A rare red-cell unit is being prepared for extended preservation using a rejuvenation process. Identify metabolic restoration as the purpose, then verify the required washing or freezing sequence rather than relabeling the original unit for direct transfusion.

Apply it

A chronically transfused patient has repeated febrile nonhemolytic reactions after other causes have been excluded. Prestorage leukocyte-reduced components address a relevant mechanism. A separate history of severe plasma-mediated allergy would require a different modification decision.

Apply it

An infant needs several small red-cell transfusions over time. Reserve appropriately prepared aliquots from one compatible donation when feasible, checking each aliquot's volume, expiration and special requirements before issue for the individual transfusion episode.

Apply it

A refrigerated red-cell component is opened at 10:00 on Monday. Its original expiration is 18:00 that evening. Although the open-system refrigerated limit would extend to Tuesday morning, the original Monday expiration remains the earlier applicable limit.

Apply it

A donor reports illness after giving blood even though initial donation testing was nonreactive. Preserve the report's link to the donation and initiate the appropriate assessment; a negative test result does not make postdonation information irrelevant.

Apply it

A filtration assessment finds very low residual leukocytes but only 75% red-cell recovery. The result supports white-cell removal yet fails the stated recovery criterion. Investigate processing performance instead of accepting the component on leukocyte count alone.

Apply it

Group A and group B parents have a group O child. Under ordinary ABO inheritance, AO and BO parental genotypes explain the result. Do not infer an impossible relationship merely from the parents' reported phenotypes.

Apply it

A D-positive patient has anti-E. Selecting another D-positive unit does not solve the problem. Identify E-negative red cells and perform the required compatibility testing, while continuing to satisfy the patient's ABO and other requirements.

Apply it

A surgical patient has a negative current screen but an old report documenting anti-K. Request K-negative units with an IAT crossmatch. Repeating the screen until it remains negative does not remove the historical compatibility requirement.

Apply it

A newborn's red cells type Lewis negative despite a family history of Lewis-positive adults. Recognize developmental expression and adsorption as the explanation. The result does not by itself imply a specimen error or abnormal red-cell production.

Apply it

For a patient with anti-M detectable only at room temperature, distinguish cold interference from clinically significant reactivity. Canadian Blood Services guidance generally recommends red cells crossmatch-compatible by indirect antiglobulin testing at 37°C without routine M-negative selection. Australian/New Zealand guidance in ANZSBT Table 2.1 recommends M-negative selection when anti-M is reactive at 37°C. These are jurisdiction-specific recommendations, not a universal U.S. requirement. For anti-S, select S-negative, antiglobulin-crossmatch-compatible red cells. In pregnancy, IgG anti-M reactive at 37°C calls for assessment of fetal antigen risk and appropriate antibody monitoring.

Apply it

Eight days after transfusion, a patient develops an unexplained hemoglobin fall and newly demonstrable anti-Jka. Review previous records and donor antigen information to assess an anamnestic delayed reaction, rather than attributing the finding solely to a new unrelated anemia.

Apply it

A weak antibody investigation includes nonreactive Fya-positive cells that are also Fyb positive. Before excluding anti-Fya, assess suitable double-dose cells under the laboratory's identification criteria, and obtain additional testing when the existing panel is insufficient.

Apply it

A patient requires cells negative for an antigen present in 98% of the relevant donor pool. Screening two random units is unlikely to solve the problem. Begin a coordinated search using typed inventory and appropriate rare-donor resources early.

Apply it

A recipient's screen is negative, but one donor unit is incompatible at the antiglobulin phase while another is compatible. Investigate the isolated incompatibility rather than assuming the screen proves that every donor must be suitable.

Apply it

A trainee predicts antibody formation solely because an antigen is frequent among donors. Ask separately whether the recipient lacks it, whether exposure occurred and how immunogenic the antigen is. Then consider the recipient's observed antibody history.

Apply it

A pregnant patient has an IgG red-cell alloantibody, and fetal testing indicates the corresponding antigen is present. This combination supports targeted fetal surveillance. An otherwise similar maternal IgM antibody does not create the same placental-transfer mechanism.

Apply it

A patient develops hemoglobinemia soon after an ABO-incompatible transfusion. Link the rapid red-cell destruction to antibody-mediated complement activation, while using clinical findings and hemolysis studies rather than the DAT alone to assess the reaction.

Apply it

A previously transfused patient has a negative pretransfusion screen, then develops a falling hemoglobin and renewed alloantibody detection one week later. Assess prior sensitization and donor antigen exposure as a coherent explanation for delayed immune destruction.

Apply it

A recently transfused patient has broad plasma reactivity and a positive DAT. Consider both autoantibody activity and antibody binding to transfused donor cells. Review transfusion timing before interpreting a positive autocontrol as proof of autoimmunity.

Apply it

A D-negative pregnant patient has newly detected anti-D after documented prophylaxis. Compare timing and prior results before labeling the patient actively alloimmunized. Conversely, established immune anti-D cannot be reversed by simply administering another prophylactic dose.

Apply it

A multiply transfused patient repeatedly has poor early platelet increments without substantial bleeding or sepsis. Investigate HLA antibodies and relevant platelet antigens rather than ordering increasingly detailed red-cell antigen matching to solve the platelet response.

Apply it

Two infants have similarly positive DAT results but different hemoglobin and bilirubin trends. Base their clinical assessment on those trends and the identified antibody rather than assuming equal disease severity from matching DAT reaction grades alone.

Apply it

A bleeding patient has an adequate platelet count but markedly reduced fibrinogen. Recognize that additional platelets do not directly replace the missing soluble substrate. Select fibrinogen replacement within the clinical plan and reassess the broader coagulation picture.

Apply it

A transplant recipient's red-cell unit is ABO compatible and antibody-screen compatible. These results address red-cell incompatibility but not donor T-cell engraftment. Verify the required irradiation status before considering the component suitable for this patient's support.

Apply it

Hypothetical adult results are anti-A 4+, anti-B 0, reverse A1 cells 1+ and B cells 4+. Repeat testing confirms the pattern. Patient cells are nonreactive with anti-A1 lectin, while the A1 positive control reacts and the A2 negative control does not. Plasma reacts with several A1 samples but not several A2 samples, selected group O cells or the patient's own cells. These findings support anti-A1 accompanying a non-A1 group A phenotype. Testing multiple appropriately selected cells helps distinguish A1 specificity from an unrelated antibody coincidentally reacting with one reagent donor. Assess reactivity at 37°C because anti-A1 is generally clinically insignificant unless reactive at that temperature.

Apply it

Consider a hypothetical patient with reliable pretransfusion typing of E-negative, K-negative, Jk(a−b+) and Fy(a−b+), without recent transfusion. All results below are untreated-cell IAT grades; 0 means nonreactive. Cell | E | K | Kidd phenotype | Duffy phenotype | IAT 1, initial | + | + | Jk(a+b−) | Fy(a−b+) | 2+ 2, initial | + | + | Jk(a−b+) | Fy(a+b−) | 2+ 3, initial | − | − | Jk(a+b−) | Fy(a+b−) | 0 4, selected | + | − | Jk(a−b+) | Fy(a−b+) | 2+ 5, selected | − | + | Jk(a+b−) | Fy(a+b−) | 0 6, selected | − | + | Jk(a−b+) | Fy(a−b+) | 0 Initially, anti-E and anti-K both fit because E and K occur together on the reactive cells. Cell 4 reacts despite lacking K, so anti-K alone cannot explain the pattern. Cells 5 and 6 express K without E and are nonreactive, providing exclusion evidence against detectable anti-K under these conditions. Cells 3 and 5 are nonreactive despite homozygous Jka and Fya expression, providing dosage-appropriate exclusion evidence against anti-Jka and anti-Fya. Anti-E explains every displayed reaction and agrees with the patient's E-negative status.

Apply it

A patient with anti-K has a positive antibody screen but a negative DAT and no recent transfusion. This is coherent if the patient's own cells lack K; the plasma antibody reacts with K-positive test cells during the IAT.

Apply it

A patient receiving daratumumab has panreactivity that disappears with DTT-treated cells. Use the validated interference pathway and account for destroyed Kell antigens when selecting blood. Disappearance of reactivity does not prove that all possible alloantibodies are absent.

Apply it

A recently transfused patient needs extended antigen matching, but serologic typing shows mixed reactions. Obtain appropriate molecular testing to help establish the patient's predicted antigen profile rather than assuming every detected antigen belongs to the patient's own cells.

Apply it

A patient has a negative current screen and confirmed ABO results, but a previous hospital documented anti-Jka. The historical antibody excludes routine electronic crossmatching; arrange corresponding antigen-negative units and the indicated serologic compatibility testing instead.

Apply it

A tube crossmatch is nonreactive at the antiglobulin phase, and added IgG-sensitized check cells remain nonreactive. Do not release the result as compatible. Investigate the failed validation and repeat the test before interpreting it.

Apply it

A patient with a negative screen has one incompatible donor crossmatch and no identification error on initial review. Investigate the discrepancy, including a donor antigen absent from screening cells, instead of dismissing the crossmatch as necessarily erroneous.

Apply it

A newborn has a positive IgG DAT and maternal alloantibody history. Testing an appropriate eluate against selected cells can establish whether the relevant antibody is bound to neonatal red cells, while hemoglobin and bilirubin establish clinical consequences.

Apply it

A panel contains nonreactive Jk(a+b+) cells, but anti-Jka remains plausible. Testing suitable Jk(a+b−) cells provides stronger evidence because double-dose expression may reveal a weak antibody that the heterozygous cells fail to demonstrate under the same conditions.

Apply it

For a patient transfused last week whose broad plasma reactivity obscures an antibody panel, use alloadsorption with appropriately selected phenotyped donor cells. The circulating red-cell sample contains transfused cells and cannot be assumed to represent only the patient's cells. For example, in a K-negative patient with underlying anti-K, residual transfused K-positive cells could adsorb anti-K during attempted autoadsorption. Selecting K-negative donor cells for an adsorption aliquot preserves anti-K in that aliquot while removing the interfering autoantibody.

Apply it

In a hypothetical anti-E plus anti-Fya mixture, matched cell pairs give these IAT results: an E-positive, Fya-negative cell changes from 1+ untreated to 3+ after ficin; an E-negative, Fya-positive cell changes from 2+ untreated to 0 after ficin; an E-negative, Fya-negative cell remains 0 in both tests. The first pair illustrates enhancement compatible with anti-E. The second illustrates loss of a ficin-sensitive target compatible with anti-Fya. Confirm the proposed specificities using additional selected untreated cells and reliable patient antigen information. These example grades illustrate a possible pattern, rather than a fixed response expected from every antibody sample.

Apply it

A current sample types group B while a reliable historical record shows group O. Pause the routine interpretation, investigate patient and specimen identification, and obtain an appropriately identified new sample rather than overwriting the historical group.

Apply it

An antenatal antibody titer appears higher after testing moves to another laboratory using a different method. Review comparability and arrange an appropriate controlled comparison before concluding that maternal antibody production has increased by the same numerical amount.

Apply it

An older patient with renal impairment develops dyspnea, hypertension and pulmonary edema after rapid transfusion with a strongly positive fluid balance. These findings support circulatory overload and should guide immediate assessment and planning of any further transfusion.

Apply it

A patient develops abrupt hypoxemia and bilateral pulmonary edema shortly after plasma transfusion, without evidence that fluid overload explains the deterioration. Assess for TRALI and other acute lung-injury causes while providing urgent respiratory support and notifying the transfusion service.

Apply it

During platelet transfusion, a patient develops sudden rigors, marked fever and hypotension. Stop the infusion, obtain urgent clinical assessment and preserve the bag and set for investigation. Arrange patient and component cultures through the reaction pathway.

Apply it

A bleeding patient has markedly reduced fibrinogen after major blood loss. Cryoprecipitate addresses the depleted fibrinogen substrate. Continue assessing platelet count and other coagulation deficits because correcting fibrinogen alone may not correct the entire bleeding disorder.

Apply it

A group A patient needs plasma, and group A and group B units are available. Group A is compatible; group B plasma contains anti-A directed at the patient's red cells. Do not choose by applying red-cell donor rules.

Apply it

Group O platelets are considered for a group A recipient. The donor plasma may contain anti-A against recipient red cells. Assess the relevant plasma-antibody risk controls instead of assuming that the group O designation guarantees universal platelet compatibility.

Apply it

A patient's count rises from 8 to 13 × 10^9/L at 30 minutes, then shows a similarly poor response to another transfusion. The repeated early increments support a refractoriness assessment, alongside review of dose and clinical consumption.

Apply it

A patient has repeatedly poor early increments without major bleeding or sepsis. HLA class I typing and antibody specificity testing can guide an immune-support strategy. A different patient with active DIC still needs the consumptive process addressed.

Apply it

A patient develops back pain and dark urine soon after red-cell transfusion starts. Stop the transfusion and trigger the reaction investigation, including identity checks. Do not wait for a DAT result before responding to the clinical warning signs.

Apply it

A stable patient with iron-deficiency anemia has no evidence of critical oxygen-delivery failure and can receive targeted treatment. Address the deficiency rather than regarding red-cell transfusion as the automatic response to every reduced hemoglobin concentration.

Apply it

Before elective surgery, a patient is found to have a correctable anemia. Investigate and treat its cause while planning blood conservation. If transfusion later becomes necessary, identify the physiologic objective and reassess whether further component exposure is needed.

Apply it

After collecting a blood-bank sample, a worker proposes recapping the used needle before carrying it to disposal. Discard the sharp directly into the nearby approved container. If the container is poorly positioned, correct its placement to support immediate disposal. Convenience alone does not satisfy the criteria for an exception.

Apply it

To prepare 2.0 mL of a 1:20 sample dilution, divide the final volume by 20. Use 0.10 mL sample and 1.90 mL diluent, then mix as required before taking material for the next step.

Apply it

An anti-A reagent correctly reacts with A cells but also reacts with the designated negative control. Withhold affected interpretations and investigate the nonspecific reaction rather than accepting the run because the positive control demonstrated strong agglutination.

Apply it

A tube opens unexpectedly and blood splashes into a worker's eye. Flush the eye promptly with water, then report the exposure and obtain the required medical assessment. Searching for the source patient's results must not delay immediate first aid.

Apply it

An automated result is correct in the analyzer record but entered incorrectly into the patient report. Treat this as a postanalytical failure and correct the reporting process; recalibrating the analyzer does not address the demonstrated error.